Group 1: Company Performance - In 2024, the company achieved operating revenue of 2.331 billion CNY and a net profit attributable to shareholders of 156 million CNY, marking a dual growth in both metrics [2] - Revenue from mainland China reached 1.177 billion CNY, while revenue from non-mainland China was 1.154 billion CNY, reflecting a year-on-year growth of 7.53% [2] - The net profit attributable to shareholders grew by 3.59% year-on-year, with a gross margin of 58.25% [3] Group 2: Cost Management - The company effectively controlled its sales expense ratio and management expense ratio, with management expenses decreasing by 1.21 percentage points and sales expenses decreasing by 1.34 percentage points in 2024 [5] Group 3: Strategic Initiatives - The company plans to continue advancing its "Smart+" strategy in 2025 to enhance performance and provide better returns to shareholders and society [3] - The company is focusing on integrating AI technologies into its operations, particularly through the MACP protocol to facilitate natural communication and collaboration among AI agents [4] Group 4: International Business Development - In Southeast Asia, the company has expanded its local teams in Thailand, Vietnam, and Malaysia, achieving over 90% localization in its talent pool [4] - The company collaborates with strategic partners like China Telecom and KPMG to enhance services for Chinese enterprises going abroad, covering industries such as automotive, electronics, and new energy [4] Group 5: Product Development - The company has made significant advancements in its AI applications and the Athena platform, launching a multimodal large model and an agent development platform [4] - The company maintains a leading market share in the PLM sector, driven by over 20 years of expertise in R&D design [6]

证券代码：300562 证券简称：乐心医疗 广东乐心医疗电子股份有限公司投资者关系活动记录表 编号：2025-006 投资者关系 活动类别 □ 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 ■其他 2025 年一季报业绩交流 参与单位名 称及人员 天风医药、中邮医药、东吴医药、申万菱信、中信证券、华夏基金、泽 源私募、银河基金、东方港湾、中欧基金、友邦保险、国联民生、长城 财富资管、天治基金、财通资管、人保养老、金科投资、兴银、优益增、 安盛浦银等线上参会的机构。 时间 2025 年 04 月 27 日（星期日）下午 14:30 地点 线上平台 上市公司接 待人员姓名 董事长、总经理：潘伟潮先生 董事、副总经理、财务总监、董事会秘书：黄林香女士 投资者关系 活动主要内 容介绍 公司本次交流通过线上平台进行，主要内容如下： 一、公司介绍及 2025 年一季度经营情况 公司聚焦数字慢病管理领域，依托在智能医疗健康、医疗级可穿戴 等领域产品创新研发、产品品质以及领先的应用技术等方面的独特优 势，将智能健康监测、大数据、AI 人工智能与医疗服务深度融合，持续 ...

Group 1: Business Impact and Market Demand - The company is actively addressing the impact of increased tariffs on optical modules by communicating with customers about cost-sharing and expanding overseas production capacity to mitigate effects [1] - Domestic demand for optical modules is expected to see significant growth compared to last year, driven by increased investment in computing power from domestic clients [2] - Overseas demand remains stable and is not showing signs of slowing down [2] Group 2: Financial Performance - The company's gross margin reached a historical high in Q1 2025, influenced by product mix, capacity release, and improved yield rates [2] - The gross margin for optical modules has also seen a noticeable increase [2] - The telecom segment's gross margin has declined year-on-year due to changes in product mix and lower sales prices, reflecting overall weak demand in the telecom market [2] Group 3: Asset Management and Procurement - Asset impairment losses are accounted for based on the age of raw materials and semi-finished products, with Q4 2024 and Q1 2025 impairments related to inventory turnover [2] - Imported optical chips are primarily sourced from Malaysia, Singapore, and Japan, while the proportion of domestic chips remains low [2] Group 4: Future Outlook and Strategy - The company aims to improve revenue and profit in 2025 compared to 2024, setting internal targets for higher performance [2] - The data communication business is expected to account for approximately 62% of the company's revenue in 2024, with further growth anticipated [2] - The global telecom transmission market is currently at a low point, but there is potential for improvement as inventory levels stabilize [3] Group 5: Technology and Product Development - The company has made early investments in silicon photonics technology, with a current monthly production capacity of 500,000 units, primarily focusing on short-distance applications [3] - Silicon photonics technology is expected to coexist with EML technology, with advantages in integration for certain optical modules [3]

证券代码：301195 证券简称：北路智控 南京北路智控科技股份有限公司投资者关系活动登记表 编号：2025-001 (1)落地进度：首个实验性项目在陕煤集团，1500 万左右，已完成验收。此外在 非煤矿山领域，与兴发集团展开合作，也开拓了无人驾驶的订单。无人驾驶产 品正式发布后，公司会加快销售工作。 | 投资者关系 | □特定对象调研 □分析师会议 □媒体采访 | | --- | --- | | 活动类别 | ☑业绩说明会 □新闻发布会 □路演活动 | | | □现场参观 □一对一沟通 □其他 | | 参与单位及 | 中信证券、中金证券、华泰证券、国金证券、国信证券、财通 证券、中泰证券、国泰海通证券、西部证券、长江证券、富国 | | | 基金、华夏基金、汇添富基金、工银瑞信基金、博时基金、中 | | 人员姓名 | 粮信托、中银基金、上银基金、兴银理财、和谐健康保险、平 | | | 安集团、群益证券投资信托、宏利基金、马可波罗中国资产管 | | | 理等投资者。 | | 时间 | 2025 年 4 月 27 日 13:30-14:30 | | 地点 | 公司会议室 | | 上市公司 | 董事长于胜利、财务负 ...

证券代码：300442 证券简称：润泽科技 润泽智算科技集团股份有限公司 投资者关系活动记录表 编号：2025-001 | | 特定对象调研 分析师会议 | | --- | --- | | 投资者关系活动 | 业绩说明会 媒体采访  | | 类别 | 新闻发布会 路演活动 | | | 现场参观 | | | 其他 | | 参与单位名称及 | 天风证券、长江证券、国投证券、中信证券、中信建投、招商证 券、兴业证券、东兴证券、德邦证券、国联民生证券、国盛证券、 国金证券、国信证券、国海证券、国泰海通证券、广发证券、开 | | 人员姓名 | 源证券、华泰证券、华金证券、华创证券、华福证券、申万宏源 | | | 证券、西部证券、西南证券、中金公司、中银证券、中泰证券、 | | | 高盛证券、UBS 等证券公司以及部分机构和个人投资者 | | 时间 | 年 月 2025 4 25 日（周五）15：00~16：00 | | 地点 | 公司通过全景网"全景路演"以网络视频直播的方式召开 2024 | | | 年度业绩说明会 | | 上市公司接待人 | 副董事长兼总经理：李笠先生 | | | 董事兼董事会秘书： ...

证券代码：002419 证券简称：天虹股份 3.购物中心和百货的转型升级方向？今年的开店计划？ 天虹数科商业股份有限公司投资者关系活动记录表 编号：2025-02 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 ☑其他 电话会议 | | 参与单位名称及 | 长江证券张彦淳；海通证券李宏科；申万宏源赵令伊、李秀琳；国信证券柳旭；开源 | | 人员姓名 | 证券黄泽鹏；中信证券林镇潘；中金公司王杰睿。 | | 时间 | 2025 年 4 月 27 日下午 14:00 | | 地点 | 公司会议室 | | 上市公司接待人 | 陈卓（董事会秘书）、罗曾琪（证券事务代表） | | 员姓名 | | | | 1.介绍公司 2025 年一季度经营情况 | | | 2025 年一季度，在国家提振消费及扩大内需的政策引导与支持下，国内零售消费 | | | 行业呈现稳健复苏态势，但有效需求增长动力仍显不足。公司积极应对外部环境变化， | | | 聚力核心业务攻坚和降本增效工作，持续增强核心竞争 ...

证券代码：300146 证券简称：汤臣倍健 汤臣倍健股份有限公司 | | 运营和投放策略，通过产品创新打造高价格带产品，搭建自主可控直播间对 | | --- | --- | | | 品牌心智进行沉淀，增加商品卡的销售和合理比例的达播合作提升公司在 | | | 抖音平台的销售规模。货架电商则会通过运营提效、增加专供品加大产品区 | | | 隔等方面助力销售。 | | | Q：2025 年全年费用指引，费用投放是否集中在下半年 | | | 公司遵循全费用/全费比动态管控原则，注重费用投产比，确保预算与 | | | 收入动态匹配。在今年既定预算目标相对谨慎稳定的整体基调下，公司将进 | | | 一步提升精细化管理能力，通过月度预算管控和销售复盘，根据实际情况动 | | | 态优化资源分配，确保费用投放的合理性。 | | | Q：蛋白粉、健力多迭代情况 | | | 两个大单品的迭代工作在去年年底基本结束，但消费环境和行业处于 | | | 持续变化中，新产品的销售暂时未达到公司预期，还需要继续关注。 | | | Q：药店渠道医保政策实施力度及持续影响 | | | 目前来看医保管理趋严已成常态化。行业层面，从人均消费额、 ...

证券代码：300138 证券简称：晨光生物 晨光生物科技集团股份有限公司 | 性。受豆粕等大宗农产品行情影响，今年以来棉籽加工行 | | --- | | 业行情回暖，公司把握市场机遇，严格执行对锁的经营模 | | 式，2025 年一季度棉籽类业务经营同比显著改善。 | | 7、公司短期借款增长比较多的原因？ | | 2025 年一季度，为准备下阶段原料采购所需资金及置 | | 换前期融资，公司新增了短期融资。因融资资金到位、计 | | 划偿还的银行借款尚未到期并偿还，一季度末账面短期借 | | 款规模增长较多，相应货币资金也大幅增长。 | | 8、2025 年公司在保健食品和中药方面有哪些新规划？ | | 保健食品 2024 年收入约 1.6 亿元，目前正在建设新的 | | 生产车间，新产能投产能够支撑公司保健食品业务规模继 | | 续增长。目前保健食品业务以 OEM 代工为主，2025 年将致 | | 力于研发新的功效明确、有晨光特色的产品，争取以卓越 | | 的品质和服务不断扩大在行业内的影响力。 | | 中成药业务仍在早期发展阶段，2024 年收入突破 1000 | | 万元，2025 年重点将放单方大 ...

Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. was established in 2002, focusing on drug research, production, and sales, particularly in pediatric and chronic disease medications [2][3] - The company has a comprehensive pharmaceutical R&D and operational management capability, with 193 drug registration certificates, including 82 national medical insurance varieties and 26 national essential drug varieties [3] Financial Performance - In 2024, the company achieved a revenue of CNY 1.45 billion, with a net profit attributable to shareholders of -CNY 540 million [4] - In Q1 2025, revenue reached CNY 377 million, a 79.16% increase compared to Q4 2024, with a net profit of CNY 56.59 million, marking a turnaround from losses [4] R&D Investment - The company invested CNY 325 million in R&D in 2024, accounting for 22.40% of its revenue [4] - In Q1 2025, R&D investment was CNY 74.23 million, an 18.71% increase year-on-year [4] Key Product Development - The innovative drug AR882 received Fast Track Designation (FTD) from the FDA in August 2024 for treating visible tophi in gout patients, addressing a global gap in oral medication for this condition [4][13] - As of March 2025, AR882 has completed patient enrollment for its pivotal Phase III clinical trials in both domestic and international settings [5][6][13] Market Outlook - The market for hyperuricemia and gout is expanding, with increasing patient numbers globally, indicating a promising market outlook for AR882 [10][12] - The company anticipates that AR882 will not only lower serum uric acid levels but also dissolve gout tophi, enhancing its therapeutic profile compared to competitors [10][11] Strategic Collaborations - The company has partnerships with Arthrosi for the overseas Phase III clinical trials of AR882, which are progressing well [12][14] - Yipinhong also holds stakes in companies like Fendi Pharmaceutical and Alpha Molecular, focusing on innovative drug development in targeted therapies [7][8] Future Plans - The company aims to continue its focus on pediatric medications and innovative chronic disease drugs, with a robust pipeline of 71 projects under development [12][15] - Future commercialization strategies for AR882 will be aligned with clinical trial progress and market demands [12][15]

Group 1: Industry Overview - In 2024, global photovoltaic installations are expected to reach approximately 460 GW, representing a year-on-year growth of 27% [1] - Global energy storage installations are projected to exceed 180 GWh in 2024, marking a 72% increase [2] - The wind power market is expected to maintain steady growth, with new installed capacity increasing from 116 GW in 2023 to 122 GW in 2024, a 5% year-on-year growth in China [2] Group 2: Company Performance - In 2024, the company achieved a revenue of 77.8 billion CNY, a 7.8% increase year-on-year, and a net profit of 11 billion CNY, up 16.9% [3] - The company’s R&D expenses reached 3.16 billion CNY in 2024, reflecting a 29% increase, with R&D personnel accounting for approximately 40% of the workforce [4] - In Q1 2025, the company reported a revenue of 19 billion CNY, a 50% increase year-on-year, and a net profit of 3.83 billion CNY, up 82% [6] Group 3: Market Dynamics - The company’s inverter shipments in 2024 reached 147 GW, a 13% increase, maintaining its leading position in the industry [5] - The energy storage business saw shipments of 28 GWh in 2024, a significant 167% increase [5] - The company’s strategy includes a focus on global marketing and service networks, with a dual approach of targeting large clients and channel development [4] Group 4: Future Outlook - The renewable energy sector is expected to continue growing, driven by the global carbon neutrality goals and the increasing share of renewable energy in primary energy consumption, currently at around 14% [7] - The company anticipates that the cost of electricity from renewable sources will continue to decrease, making it the cheapest power source in the future [7] - The company aims to achieve a storage shipment target of 40-50 GWh in 2025, although this may be impacted by U.S. tariff uncertainties [8]